The trial demonstrated that BCMA and CD19 CAR T-cell infusions can be applied as consolidation therapy after tandem ASCT to increase in-depth responses in newly diagnosed (ND) MM patients with high risk features. Here, CD19 is linked to Miyoshi myopathy.